RecruitingNot applicableNCT04942080
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Angers
- Intervention
- CALR allele burden quantification(biological)
- Enrollment
- 260 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2030
Study locations (10)
- CHU Angers, Angers, France
- Chu Bordeaux, Bordeaux, France
- Chu Brest, Brest, France
- Ch Cholet, Cholet, France
- Ch Le Mans, Le Mans, France
- Ch Morlaix, Morlaix, France
- AP-HP Henri Mondor, Paris, France
- Chu Poitiers, Poitiers, France
- Ch Quimper, Quimper, France
- Chu Tours, Tours, France
Collaborators
Ligue contre le cancer, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04942080 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.